ITM Charts A Path From Radionuclides To Radiotherapeutics And Attracts Financing

GEP-NET Candidate In Phase III

 
• By John Davis
  
radioligand cancer cell
• Source: Alamy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Anticancer

More from Therapeutic Category